Pay attention to the effect of anti-vascular endothelial growth factor drugs on neurodevelopment in children with retinopathy of prematurity
- Author:
- No author available
- Journal Title:
- Chinese Journal of Ocular Fundus Diseases
- Issue:
- 7
- DOI:
- 10.3760/cma.j.cn511434-20220523-00319
- Key Word:
- 早产儿视网膜病;血管生成抑制剂;神经发育;述评;Retinopathy of prematurity;Angiogenesis inhibitors;Neurodevelopmental;Editorial
Abstract： Retinopathy of prematurity (ROP) is one of the leading causes of visual impairment in children. As understanding on the pathogenesis of ROP accumulated, anti-vascular endothelial growth factor (VEGF) drugs and their application have changed the treatment mode. Anti-VEGF therapy, with convenient operation and clear efficacy, has become an important treatment method for ROP. However, due to the dysfunction of organs in children with ROP, anti-VEGF drugs can enter blood circulation after intravitreal injection and then lead to temporarily reduction of the VEGF level in the blood, which may theoretically cause adverse effects on the development of all organs (especially the brain) in children with ROP. Therefore, it's necessary to pay attention to the effect of anti-VEGF drugs on neurodevelopment in children with ROP, strictly grasp the indications, and standardize its clinical application, so as to continuously improve the overall prognosis of ROP.
- [1]Parag K Shah,Vishma Prabhu,Smita S Karandikar,etc.Retinopathy of prematurity:Past, present and future[J].2016,(1).
- [2]Wong, Ryan K.,Hubschman, Sasha,Tsui, Irena.Reactivation of Retinopathy of Prematurity after Ranibizumab Treatment[J].2015,35(4).
- [3]Natarajan, Girija,Shankaran, Seetha,Nolen, Tracy L.,etc.Neurodevelopmental Outcomes of Preterm Infants With Retinopathy of Prematurity by Treatment[J].2019,144(2).
- [4]中华医学会儿科学分会眼科学组.早产儿视网膜病变治疗规范专家共识[J].2022,38(1).
- [5]Xuting Chen,Lin Zhou,Qi Zhang,etc.Serum Vascular Endothelial Growth Factor Levels before and after Intravitreous Ranibizumab Injection for Retinopathy of Prematurity[J].2019,2019.
- [6]Chung-Ying Huang,Reyin Lien,Nan-Kai Wang,etc.Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity[J].2018,256(3).
- [7]Vutskits, Laszlo,Xie, Zhongcong.Lasting impact of general anaesthesia on the brain: mechanisms and relevance[J].2016,17(11).
- [8]McLeod,D.S.,Wiegand,S.J.,Bhutto,I.,etc.Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog[J].2011,52(7).
- [9]Morin, Julie,Thuy Mai Luu,Superstein, Rosanne,etc.Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity[J].2016,137(4).
- [10].Retinopathy of Prematurity[J].2017,78(2).
- [11]海峡两岸医药卫生交流协会眼科专业委员会小儿视网膜学组,中华医学会眼科学分会眼底病学组.早产儿视网膜病变玻璃体腔注射抗血管内皮生长因子药物治疗的专家共识[J].2021,37(11).
- [12]汤加.血管内皮生长因子的神经保护作用[J].2020,(1).
- [13]Mitsuru,Arima,Masato,Akiyama,Kohta,Fujiwara,etc.Neurodevelopmental outcomes following intravitreal bevacizumab injection in Japanese preterm infants with type 1 retinopathy of prematurity.[J].2020,15(3).
- [14]Christoforidis, John Byron,Briley, Karen,Binzel, Katherine,etc.Systemic Biodistribution and Intravitreal Pharmacokinetic Properties of Bevacizumab, Ranibizumab, and Aflibercept in a Nonhuman Primate Model[J].2017,58(13).
- [15]Kennedy KA,Chuang AZ,Mintz Hittner HA.Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.[J].2011,364(7).
- [16]Mikael Norman,"name":"Department of Neonatal Medicine, Karolinska University Hospital, Stockholm, Sweden","name":"Swedish Neonatal Quality Registry, Ume\u00e5, Sweden",etc.Prevalence of Severe Visual Disability Among Preterm Children With Retinopathy of Prematurity and Association With Adherence to Best Practice Guidelines[J].2019,2(1).
- [17]杨小元,蔡瑜婷,李芸.日本眼科学会《早产儿视网膜病变的抗VEGF疗法临床指南》解读[J].2021,(11).